We are a biopharmaceutical company dedicated to creating transformative treatments to address high unmet need rare diseases.
We leverage technological advances to target molecules and pathways with proven roles in disease biology.
By applying the right science and the right development strategies, We aim to rapidly advance new treatments for patients with high unmet medical need.
We are building a pipeline of novel drugs to treat diseases with no treatment options. Our Aldose Reductase Inhibitor (ARI) franchise is in development across multiple disease areas, including Galactosemia, SORD Deficiency and other diseases.
Our mission is to create transformative treatments for patients with rare disease.
By applying the right science and the right development strategies, We aim to rapidly advance new treatments for patients with high unmet medical need.
